Zobrazeno 41 - 50
of 84
pro vyhledávání: '"329"'
Autor:
Adam Cuker, Maria Eva Mingot-Castellano, Natasha Satkunam, Julie Grabell, Patrick F. Fogarty, Maria Elisa Mancuso, Pål Andre Holme, Christoph Bidlingmaier, Meera Chitlur, Prasad Mathew, Paula D. James, Wilma M. Hopman, Johnny Mahlangu
Publikováno v:
Blood. 128:875-875
Background: Hemophilia carriers report abnormal bleeding, even when factor VIII or IX levels are normal. Information comparing bleeding events between carriers and women with other inherited bleeding disorders is lacking. Purpose: The purpose of our
Autor:
Mark D. Fleming, David P. Steensma, Vilmarie Rodriguez, Shakila P. Khan, Leah A. Schmelkin, Mrinal M. Patnaik, Naseema Gangat, Matthew T. Howard, Alexandra P. Wolanskyj
Publikováno v:
Blood. 126:3355-3355
Background: Ring sideroblasts (RS) are erythroid precursors with perinuclear mitochondrial iron accumulation seen in clonal disorders, such as myelodysplastic syndromes (MDS), and non-clonal conditions, including copper deficiency, lead poisoning, an
Autor:
Maurizio Zangari, Antje Hoering, Jeffery R. Sawyer, Pingping Qu, Bart Barlogie, Joshua Epstein, Christoph Heuck, Erming Tian, Frits van Rhee, Gareth J. Morgan
Publikováno v:
Blood. 126:2982-2982
Introduction In multiple myeloma (MM), deletion of chromosome 17 p13 (del17p) is a poor prognostic feature. The percentage of cells carrying an abnormality has been reported to be important with thresholds of 20% being taken generally but thresholds
Autor:
Muneer H. Abidi, Andy I. Chen, Tamas Masszi, Auayporn Nadamanee, Veronika Bachanova, Naomi N. H. Hunder, Patrick J. Stiff, Simonetta Viviani, Anna Sureda, Angelo Michele Carella, Dirk Huebner, Jan Walewski, Emily K. Larsen, Jerzy Holowiecki, Craig H. Moskowitz, Dzhelil Osmanov, John W. Sweetenham, Edward Agura
Publikováno v:
Blood. 126:3172-3172
Introduction The AETHERA trial is a phase 3, randomized, placebo-controlled trial (ClinicalTrials.gov #NCT01100502), which evaluated whether post-ASCT consolidation treatment with brentuximab vedotin (BV) could prevent disease progression in Hodgkin
Autor:
Genovefa A. Papanicolaou, Yao-Ting Hayden Huang, Victoria Gonzalez, Anna Kaltsas, Marina Kerpelev, Yeon Joo Lee, Seong Jin Kim
Publikováno v:
Blood. 126:3303-3303
Background: Streptococcus pneumoniae is a major cause of sepsis, pneumonia and meningitis leading to significant morbidity and mortality. Invasive pneumococcal disease (IPD) and mortality rates in cancer patients (pts) are higher than in the general
Autor:
Nicola Vianelli, Francesca Palandri, Margherita Perricone, Massimo Breccia, Nicola Polverelli, Roberto Latagliata, Emanuela Ottaviani, Michele Cavo, Giuseppe A. Palumbo, Lucia Catani, Giuliana Alimena, Francesco Merli, Giovanni Martinelli, Alessia Tieghi
Publikováno v:
Blood. 126:1614-1614
Introduction It is acknowledged that an accurate histological diagnosis may distinguish Essential Thrombocythemia (ET) from early Primary Myelofibrosis (early-PMF), which is projected to worse outcome in terms of survival and disease evolution into a
Publikováno v:
Blood. 126:4714-4714
Background Studies of hospital discharge data and large observational cohorts show that the incidence of venous thromboembolism (VTE) varies by race. We sought to determine the incidence of VTE in each of the following ethnic groups Caucasians, Afric
Autor:
Pablo J. Muxi, Bjorn Andreasson, Peter L. Johansson, Robyn M. Scherber, Dana Ranta, Stefanie Slot, Heidi E. Kosiorek, Dolores Hernández-Maraver, Amylou C. Dueck, Xiujuan Sun, Martin Griesshammer, Ana Kerguelen Fuentes, Peihong Zhang, Francesco Passamonti, Holly L. Geyer, Federico Sackmann, Zefeng Xu, Gabriel Etienne, Deepti Radia, Frank Stegelmann, Andreas Reiter, Tiziano Barbui, Jean-Christophe Ianotto, Suzan Commandeur, Peter A. W. te Boekhorst, Zhijian Xiao, Sonja Zweegman, Harry C. Schouten, Gunnar Birgegård, Carlos Besses, Françoise Boyer, Giovanni Barosi, Ruben A. Mesa, Alessandro Rambaldi, Jean-Jacques Kiladjian, Maria Grazia Ferrari, Thomas Lehmann, Heike L. Pahl, Lydia Roy, Jan Samuelsson, Francisco Cervantes, Alessandro M. Vannucchi, Konstanze Döhner, Yue Zhang, Karin Bonatz, Junqing Xu, Robert Peter Gale, Norman Maldonado, Jean-Yves Cahn, Claire N. Harrison
Publikováno v:
Blood. 126:4080-4080
Background Myelofibrosis (MF) is a clonal myeloproliferative neoplasm (MPN) associated with a high degree of symptomatology, progressive cytopenias and potential to transform into acute myelogenous leukemia (AML). Thrombocytopenia amongst MF patients
Autor:
Jennifer S. Temel, Tanya Keenan, Yi-Bin Chen, Harry VanDusen, Areej El-Jawahri, Daniel J. DeAngelo, Amir T. Fathi, Thomas W. LeBlanc, Philip C. Amrein, David P. Steensma, Lara Traeger, Richard Stone, Karen K. Ballen, Martha Wadleigh, Gregory A. Abel, Gabriela S. Hobbs
Publikováno v:
Blood. 126:2104-2104
Introduction: Older adults (≥ 60 years) with acute myeloid leukemia (AML) generally have a poor prognosis and a high rate of health care utilization including intensive care unit (ICU) admissions. While the outcomes of older patients with advanced
Autor:
Lucia Masarova, Taghi Manshouri, Sherry Pierce, Prithviraj Bose, Naveen Pemmaraju, Srdan Verstovsek, Naval Daver, Hagop M. Kantarjian, Jorge E. Cortes
Publikováno v:
Blood. 126:4069-4069
Introduction: Clinical characteristics of post-essential thrombocythemia/polycythemia vera myelofibrosis "post ET/PV-MF" are not well defined as for primary myelofibrosis "MF". Objective: We aimed to identify morphological, clinical and prognostic ch